Shanghai Sodi Biotechnology

Shanghai Sodi Biotechnology is a clinical-stage biotechnology company headquartered in Shanghai, China, dedicated to the development of next-generation cell therapies for oncology. The company utilizes its proprietary SODI-CART platform to engineer chimeric antigen receptor T-cells with improved persistence and anti-tumor activity. Its primary focus is on hematological malignancies, with lead programs targeting CD19 and BCMA for the treatment of refractory lymphomas and multiple myeloma. Sodi Biotechnology aims to provide more accessible and effective immunotherapy options through innovative cell engineering and optimized manufacturing processes. The company is actively advancing its pipeline through early-stage clinical trials in China, seeking to address unmet needs in the field of cancer immunotherapy.